Kevin Yang ⎜Mar 25, 2019 ⎜ Industry
5D3 is a new high-affinity murine monoclonal antibody specific for prostate-specific membrane antigen (PSMA). PSMA is a target for the imaging and therapy of prostate cancer. 111In-labeled antibodies have been used as surrogates for 177Lu/90Y-labeled therapeutics. We characterized 111In-DOTA-5D3 by SPECT/CT imaging, tissue biodistribution studies, and dosimetry.
Tags: immunoimaging monoclonal antibody prostate cancer PSMA SPECT SPECT/CT
David T. Drummond ⎜Apr 6, 2018 ⎜ Industry
Key findings of the study:
Kevin Yang ⎜Mar 20, 2018 ⎜ Industry
99mTc-sestamibi CZT-SPECT is technically feasible and can provide similar result to 15O-water PET for detecting impaired myocardial flow reserve and abnormal fractional flow reserve in patients with coronary artery disease. This study highlights the diagnostic value of using 99mTc -sestamibi for patients with coronary artery disease.
The WATERDAY study: Denis Agostini & Vincent (more…)
Tags: PET Radiopharmaceuticals SPECT
Kevin Yang ⎜Mar 12, 2018 ⎜ Industry
Osteoclast activity is an important factor in the pathogenesis of skeletal metastases and is a potential therapeutic target. This study aimed to determine if selective uptake of 99mTc-maraciclatide, a radiopharmaceutical targeting αvβ3 integrin, occurs in prostate cancer (PCa) bone metastases and to observe the changes following systemic therapy. (more…)
Tags: Radiopharmaceuticals SPECT Tc-99m